Functional phenotyping of human plasma using a 361‐fluorogenic substrate biosensing microarray
暂无分享,去创建一个
Scott L Diamond | W. S. Denney | S. Diamond | J. Ellman | Cleo M. Salisbury | Jonathan A Ellman | D. Gosalia | William S Denney | Cleo M Salisbury | Dhaval N Gosalia
[1] S. Iwanaga,et al. New Fluorogenic Substrates for α-Thrombin, Factor Xa, Kallikreins, and Urokinase , 1977 .
[2] K. C. Jones,et al. A Model for the Stoichiometric Regulation of Blood Coagulation* , 2002, The Journal of Biological Chemistry.
[3] C. Lawson,et al. Solving least squares problems , 1976, Classics in applied mathematics.
[4] J. Oldenburg,et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. , 2001, Blood.
[5] Scott L Diamond,et al. Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays , 2005, Proteomics.
[6] Wylie Burke,et al. Genomics as a probe for disease biology. , 2003, The New England journal of medicine.
[7] G. Broze,et al. Factor XI activation in a revised model of blood coagulation , 1991, Science.
[8] Scott L Diamond,et al. Printing chemical libraries on microarrays for fluid phase nanoliter reactions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Abrahams,et al. The Functional Integrity of the Serpin Domain of C1-inhibitor Depends on the Unique N-terminal Domain, as Revealed by a Pathological Mutant* , 2003, Journal of Biological Chemistry.
[10] U. Okamoto,et al. Production of the modified form of human plasminogen in the plasma activated by urokinase. , 1983, The Japanese journal of physiology.
[11] C. Hack,et al. Modulation of Contact System Proteases by Glycosaminoglycans , 1996, The Journal of Biological Chemistry.
[12] L. Chao,et al. Novel Roles of Kallistatin, a Specific Tissue Kallikrein Inhibitor, in Vascular Remodeling , 2001, Biological chemistry.
[13] J. Griffin,et al. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[14] Thomas Orfeo,et al. The Significance of Circulating Factor IXa in Blood* , 2004, Journal of Biological Chemistry.
[15] K. Mann,et al. Tissue factor activity in whole blood. , 2005, Blood.
[16] S. Diamond,et al. High Throughput Substrate Specificity Profiling of Serine and Cysteine Proteases Using Solution-phase Fluorogenic Peptide Microarrays* , 2005, Molecular & Cellular Proteomics.
[17] Y. Nemerson,et al. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.
[18] N. Anderson,et al. The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.
[19] L. Seipel,et al. The thrombolytic paradox. , 2001, Thrombosis research.
[20] Francesco Leonetti,et al. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin , 2000, Nature Biotechnology.
[21] T. Veenstra,et al. The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.
[22] Charles L. Lawson,et al. Solving least squares problems , 1976, Classics in applied mathematics.
[23] H. Kato,et al. Clinical‐scale high‐throughput human plasma proteome analysis: Lung adenocarcinoma , 2005, Proteomics.
[24] J. Griffin,et al. The biochemistry and pathophysiology of the contact system of plasma. , 1982, Advances in immunology.
[25] Kenneth G. Mann,et al. Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.
[26] E. Diamandis. Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.
[27] K. Mann,et al. The dynamics of thrombin formation. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[28] E. Petricoin,et al. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection , 2004, Toxicologic pathology.
[29] G. Ewald,et al. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. , 1995, Circulation.
[30] Pieter H. Reitsma,et al. Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.
[31] P. Schoen,et al. The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin. , 1987, The Journal of biological chemistry.
[32] S. Iwanaga,et al. New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase. , 1977, Journal of Biochemistry (Tokyo).
[33] E. Davie,et al. Waterfall Sequence for Intrinsic Blood Clotting , 1964, Science.
[34] M. Mayer,et al. Biochemical and biological aspects of the plasminogen activation system. , 1990, Clinical biochemistry.
[35] D. Rijken,et al. Basic principles in thrombolysis: regulatory role of plasminogen. , 2001, Thrombosis research.
[36] Scott L Diamond,et al. Blood coagulation kinetics: high throughput method for real-time reaction monitoring , 2004, Thrombosis and Haemostasis.
[37] M. Ferrari,et al. Clinical proteomics: Written in blood , 2003, Nature.